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Abstract
Background: Daptomycin is a novel cyclic lipopeptide whose bactericidal activity is not affected
by current antibiotic resistance mechanisms displayed by S. aureus clinical isolates. This study
reports the therapeutic activity of high-dose daptomycin compared to standard regimens of
oxacillin and vancomycin in a difficult-to-treat, rat tissue cage model of experimental therapy of
chronic S. aureus foreign body infection.
Methods: The methicillin-susceptible S. aureus (MSSA) strain I20 is a clinical isolate from catheter-
related sepsis. MICs, MBCs, and time-kill curves of each antibiotic were evaluated as recommended
by NCCLS, including supplementation with physiological levels (50 mg/L) of Ca2+ for daptomycin.
Two weeks after local infection of subcutaneously implanted tissue cages with MSSA I20, each
animal received (i.p.) twice-daily doses of daptomycin, oxacillin, or vancomycin for 7 days, or was
left untreated. The reductions of CFU counts in each treatment group were analysed by ANOVA
and Newman-Keuls multiple comparisons procedures.
Results: The MICs and MBCs of daptomycin, oxacillin, or vancomycin for MSSA strain I20 were
0.5 and 1, 0.5 and 1, or 1 and 2 mg/L, respectively. In vitro elimination of strain I20 was more rapid
with 8 mg/L of daptomycin compared to oxacillin or vancomycin. Twice-daily administered
daptomycin (30 mg/kg), oxacillin (200 mg/kg), or vancomycin (50 mg/kg vancomycin) yielded
bactericidal antibiotic levels in infected cage fluids throughout therapy. Before therapy, mean (±
SEM) viable counts of strain I20 were 6.68 ± 0.10 log10 CFU/mL of cage fluid (n = 74). After 7 days
of therapy, the mean (± SEM) reduction in viable counts of MSSA I20 was 2.62 (± 0.30) log10 CFU/
mL in cages (n = 18) of daptomycin-treated rats, exceeding by >2-fold (P < 0.01) the viable count
reductions of 0.92 (± 0.23; n = 19) and 0.96 (± 0.24; n = 18) log10 CFU/mL in cages of oxacillin-
treated and vancomycin-treated rats, respectively. Viable counts in cage fluids of untreated animals
increased by 0.48 (± 0.24; n = 19) log10 CFU/mL.
Conclusion:  The improved efficacy of the twice-daily regimen of daptomycin (30 mg/kg)
compared to oxacillin (200 mg/kg) or vancomycin (50 mg/kg) may result from optimisation of its
pharmacokinetic and bactericidal properties in infected cage fluids.
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Background
Infections due to Staphylococcus aureus associated with for-
eign implants, such as orthopaedic prostheses and intra-
vascular devices, are very difficult to manage by
antimicrobial therapy alone and frequently require the
removal of infected materials [1]. The growing proportion
of clinical isolates of methicillin-resistant S. aureus
(MRSA) displaying multidrug resistance not only against
all semi-synthetic penicillins and penems, but also fre-
quently against macrolides, aminoglycosides, fluoroqui-
nolones [2-4], and glycopeptides [3,5-7] recently
prompted the development of novel antimicrobial agents
active against such dangerous pathogens.
Among recently developed agents overcoming antibiotic
resistance in MRSA but also highly active against methicil-
lin-susceptible staphylococci, the lipopeptide daptomycin
[8-11] was already discovered in the 1980s by Lilly
Research Laboratories that stopped its clinical develop-
ment in 1991 due to reports of potential skeletal muscle
toxicity. In 1997, daptomycin development was resumed
by Cubist Pharmaceuticals [12] and its clinical use
approved by FDA in 2003 for the treatment of compli-
cated skin and soft tissue infections (CSSSIs) [11,13].
Daptomycin is known to exhibit calcium-dependent
binding to bacterial cytoplasmic membranes which leads
to disruption of membrane function [14]. Daptomycin is
uniformly potent in vitro against S. aureus clinical isolates
in large surveillance studies [11,15-18]. An interesting
property of daptomycin is its rapid bactericidal activity in
vitro [9,12,19,20] and in vivo [9,21-23], but this bacteri-
cidal activity is concentration-dependent and its optimal
expression may sometimes require levels equivalent to 8-
fold the lipopeptide MIC for a given strain [12,19]. The
relatively high protein binding and low volume of distri-
bution of daptomycin recorded in humans or animal
models represent a difficult challenge for defining a dos-
ing schedule exerting optimal bactericidal activity against
major categories of serious S. aureus infections [12,21-29]
in various deep-seated compartments though minimizing
skeletal muscle side-effects [30,31]. Another issue is the
recently shown observation that pulmonary surfactant
interfered with daptomycin antimicrobial activity thus
providing a likely explanation for treatment failures in
clinical trials of community-acquired pneumonia and
animal models of gram-positive pneumonia [28].
We previously described an animal model for evaluating
the in vivo activity of various bactericidal antibiotics
against localized chronic foreign body infections due to S.
aureus [32-38]. This model consists in perforated Teflon
cylinders, named tissue cages, which are subcutaneously
implanted in rats and infected three to four weeks after
surgical implantation by percutaneous local inoculation
of 105 CFU of methicillin-susceptible (MSSA) or methicil-
lin-resistant (MRSA) strains of S. aureus, yielding sus-
tained bacterial viable counts in tissue cage fluids for
several weeks [32]. The presence of the inflammatory exu-
dative fluid inside tissue cages, designated as tissue cage
fluid (TCF), allows a direct assessment of the levels and
pharmacokinetic properties of any antimicrobial agent
that accumulates into this compartment after systemic
administration. Drug efficacy is evaluated by comparing
quantitative cultures of each cage fluid before and after 7
days of intensive antimicrobial therapy [32]. Several stud-
ies have shown that systemic administration of various
categories of antibiotics can deliver adequate levels of
antimicrobial agents in TCFs [32-36]. In those studies, the
nearly continuous presence of bactericidal levels of each
antimicrobial was required throughout the 7-day thera-
pies to obtain a significant reduction of at least one log10
CFU of MSSA or MRSA per ml of TCF, as shown with van-
comycin [32], oxacillin and imipenem [33], and several
fluoroquinolones including sparfloxacin and tema-
floxacin [35], levofloxacin and trovafloxacin [36]. With
respect to the low efficacies of 7-day monotherapies with
previously tested antimicrobial agents against S. aureus
chronically infecting tissue cages, the concentration-
dependent, highly bactericidal activity of daptomycin
seemed to be promising in this model.
A first study (sponsored by Lilly and referred to as the dap-
tomycin no 1-study) was initiated in 1991 for evaluating
daptomycin in the rat model of tissue cage infections. The
study protocol was composed of two arms, the first one
assessing in vivo activity of daptomycin and comparators
against MSSA-infected and the second one against MRSA-
infected tissue cages. Because of concern with potential
reduction of drug efficacy due to high protein binding, a
twice-daily regimen of 30 mg/kg daptomycin was selected
for the daptomycin no 1-study, which resulted in very
high levels of daptomycin in TCFs and led to impressive
reductions in cage fluid viable counts in the MSSA arm
that was the only one to be completed. In contrast, the
MRSA arm of the daptomycin no 1-study was interrupted
by Lilly's decision to suspend the development and exper-
imental testing of daptomycin, which left data from the
daptomycin no 1-study essentially unpublished (except-
ing for a brief report) [39].
Following resumption of daptomycin clinical develop-
ment by Cubist in 1997, we initiated a second study
(referred to as the daptomycin no 2-study) using a modi-
fied protocol that took into consideration the lower toxic-
ity of once-daily administration of daptomycin [30,31].
With respect to the very high levels recorded in TCFs dur-
ing the daptomycin no 1-study, we anticipated that a 50%
reduction in drug dosage, consisting in a single daily
administration of 30 mg/kg daptomycin, would still
deliver high, continuously bactericidal drug levels forBMC Infectious Diseases 2006, 6:74 http://www.biomedcentral.com/1471-2334/6/74
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therapy in S. aureus-infected cage fluids. Unexpectedly, the
TCF levels recorded with the once-daily regimen of 30 mg/
kg daptomycin turned out to be much lower than those
anticipated from the 50% reduction of the previously
used twice-daily regimen administered in the daptomycin
no 1-study [37]. While the drug levels reached in TCFs by
the once-daily 30 mg/kg daptomycin regimen were still
over the minimal bactericidal concentration and led to
significant viable count reductions in S. aureus-infected
cage fluids [37], those drug levels were clearly inferior to
the 8-fold levels over the MIC of the infecting organism
recommended for optimal daptomycin bactericidal activ-
ity against S. aureus [8,9,12,21].
In the context of recently presented pharmacological,
experimental, and clinical studies exploring the safety and
efficacy of higher once-daily doses of daptomycin [29,40-
42] for treating serious gram-positive infections (e.g. S.
aureus bacteremia, endocarditis, osteomyelitis), compared
to the FDA-approved 4 mg/kg daily regimen for compli-
cated skin and skin-structure infections (CSSSIs), the pres-
entation of pharmacokinetic and efficacy data obtained
during the daptomycin no 1-study gains increased rele-
vance. The aims of this report are to (i) show the impact
of the twice-daily 30 mg/kg daptomycin regimen in the
therapy of chronically infected tissue cages compared to
oxacillin and vancomycin; (ii) emphasize the major dif-
ferences in TCF drug levels reached by administration of a
twice-daily compared to once-daily 30 mg/kg daptomycin
regimen [37]; (iii) discuss the pharmacokinetic and phar-
macodynamic factors that may contribute to daptomycin
efficacy in our hard-to-treat rat tissue cage model of for-
eign body infections as well as other infection models or
clinical situations.
(An abstract form of this study was presented at the 42nd
Intersci. Conf. Antimicrob. Agents Chemother., abstr.
1904, 2002) [39].
Methods
Bacterial strain
The methicillin-susceptible S. aureus (MSSA) strain I20 is
a previously described clinical isolate from catheter-
related sepsis, which is highly virulent in the rat model of
chronic S. aureus tissue cage infection [33,43]. Strain I20
is uniformly susceptible to all antibiotics except penicil-
lin.
Besides the strain used for the animal study, a previously
mentioned collection of 107 S. aureus clinical strains iso-
lated before 1991 in the University Hospital of Geneva
[33] were also tested for in vitro susceptibility to dapto-
mycin. They comprised 57 MSSA and 50 MRSA strains.
Antimicrobial agents
All experimental in vitro and in vivo results reported in
the daptomycin no 1-study, also including the 107 clini-
cal isolates tested for in vitro susceptibility, were recorded
in 1991 using a single batch of quality-controlled dapto-
mycin powder supplied by Ely Lilly (Giessen, Germany).
Daptomycin solutions were freshly prepared in distilled
sterile water, namely at a concentration of 5 mg/mL for in
vitro studies and 7.5 mg/L for in vivo studies. Oxacillin
(Sigma Chemical, St. Louis, Mi) was freshly dissolved in
distilled water at a concentration of 20 mg/ml. Commer-
cially available vancomycin hydrochloride (Lilly) was sol-
ubilized as recommended by the manufacturer.
In vitro studies
The MICs of oxacillin and vancomycin for strain I20 were
determined in cation-adjusted Mueller-Hinton broth
(CAMHB) containing 20-25 mg/L Ca2+ and 10-12.5 mg/L
Mg2+ by the standard tube macrodilution method with an
average inoculum of 106 CFU/mL as described by the
Clinical Laboratory Standards Institute (CLSI) [44]. For
daptomycin MIC, CAMHB was supplemented with addi-
tional calcium to a physiological concentration of 50 mg/
L Ca2+ (CSMHB).
To screen for the possible carryover effects of each antibi-
otic during the MBC determinations, 0.1-mL portions
were taken from all tubes with no visible growth. These
were subcultured, either undiluted or diluted 10-fold in
saline, on Mueller-Hinton agar (MHA) for 36 h at 37°C.
The MBC was defined as the lowest concentration that
killed 99.9% of the original inoculum.
Each MIC and MBC determination was performed three
times and the modal values are presented. In additional
control experiments, MICs and MBCs were performed in
CAMHB supplemented with 50% TCF.
Killing kinetic studies
0.1-mL portions containing 106  CFU of strain I20
(obtained from exponential-phase cultures) were added
to sterile plastic tubes containing 1 mL of either CSMHB
containing 8 mg/L of daptomycin, or CAMHB containing
8 mg/L of oxacillin or vancomycin, in a shaking waterbath
at 37°C. The number of viable organisms was determined
by subculturing 50 µL of 10-fold diluted portions on
MHA after 0, 2, 4, 6, and 24 h of incubation. Colonies
were enumerated with a laser colony counter (Spiral Sys-
tem) after 48 h of incubation at 37°C. The detection limit
was 2 log10 CFU/mL. No significant carryover of antibiot-
ics was observed by using these experimental conditions.
Each killing kinetic experiment was repeated three times
and results from one representative experiment are pre-
sented.BMC Infectious Diseases 2006, 6:74 http://www.biomedcentral.com/1471-2334/6/74
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Treatment of chronic tissue cage infections
All animal studies of the daptomycin no 1-study were per-
formed in 1991. These animal studies followed ethical
guidelines of that time period and received legal approval
from the Veterinary Office of the State of Geneva. Subcu-
taneous surgical implantation of four tissue cages per ani-
mal was performed as described [32] by using Wistar rats
that were anaesthetised with an intraperitoneal (i.p.)
injection of a mixture of ketamine (90 mg/kg) and xyla-
zine (5 mg/kg). At 3 weeks post-implantation, TCF was
aspirated and checked for sterility. To establish a chronic
S. aureus infection, tissue cages were inoculated with 0.1
mL of saline containing 0.2 × 106 to 2 × 106 CFU of a
washed overnight culture of strain I20 in CAMHB. Three
weeks later, all tissue cages containing more than 105
CFU/mL of TCF were included in the therapeutic proto-
cols.
Rats infected with strain I20 were randomised to receive
(by the i.p. route for 7 days) twice-daily regimens of either
daptomycin (30 mg/kg), oxacillin (200 mg/kg), or vanco-
mycin (50 mg/kg), or were left untreated. At 12 h after the
last injection of antibiotic, quantitative cultures of 10-fold
serially diluted TCF were performed on MHA. To optimise
the yield of viable bacteria, TCF were briefly sonicated (60
W, 1 min) to disrupt the biofilm and phagocytic cells
before the serial dilutions and plating. Plates were incu-
bated for 24-48 h at 37°C. The detection limit was one
colony equivalent to 2 log10 CFU/mL of TCF. The differ-
ences in CFU counts between day 1 and day 8 were deter-
mined and expressed as delta log10CFU/mL. For each
treatment group, results were expressed as means ± stand-
ard errors of the means (SEM). Comparison of bacterial
counts in the different groups was performed by ANOVA
and Newman-Keuls multiple comparisons procedures
using Microsoft Excel® 2000 software [45]. Data were con-
sidered significant when P was < 0.05 by using two-tailed
significance levels.
To check for potential side effects of the twice-daily 30
mg/kg daptomycin regimen, serum samples of the dapto-
mycin-treated and control rats were collected at day 8 for
determination of liver, kidney, and muscle enzyme mark-
ers, namely aspartate aminotransferase (ASAT) and
alanine aminotransferase (ALAT) activities, serum creati-
nine, and creatine kinase, respectively, using standard
analytical methods.
Pharmacokinetics of antimicrobial agents
The pharmacokinetic levels of daptomycin were deter-
mined in TCF of uninfected rats, at various time intervals
(0, 2, 4, 6, and 12 h) on day 4 and day 7 of twice-daily
administration of 30 mg/kg daptomycin as described in
the daptomycin no 2-study [37]. S. aureus-infected tissue
cage fluids were not assayed to avoid potential interfer-
ence with the daptomycin microbiological assay and min-
imize plasma contamination of TCF samples. Plasma
daptomycin levels were determined on rat blood also col-
lected from uninfected rats by periorbital puncture at var-
ious time intervals (0.25, 0.5, 1, 2, 4, 6, 8, and 12 h) after
i.p. administration of this antibiotic. For each time point,
the mean (± SEM) daptomycin levels in plasma from four
animals was determined.
The concentrations of daptomycin in rat plasma or TCF
were estimated by a previously described microbiological
assay [46] excepting for the use of Antibiotic medium 11
and Sarcina lutea as the test strain [37]. To avoid a poten-
tial bias due to protein binding, all plasma or TCF samples
were diluted with 1 volume of PBS and assayed in dupli-
cate, with reference to a range of standard concentrations
(1-128 mg/L) of daptomycin, also prepared in duplicate
in PBS supplemented with 50% plasma or TCF, respec-
tively. The correlation coefficients of daptomycin stand-
ard curves were generally ≥ 0.99, yielding intra-assay CVs
of ± 10%. Under these experimental conditions, the limit
of detection of the daptomycin assay was 1 mg/L. For each
time point, the mean (± SEM) daptomycin levels in TCF
from six animals were determined.
The areas under the concentration-time curve (AUC) of
daptomycin in rat plasma or TCF were estimated from 0
to 12 h (AUC0-12) by the linear trapezoidal rule. For com-
parison with a previously reported AUC0-24 in the dapto-
mycin no 2-study, under a once-daily 30 mg/kg
daptomycin regimen [37], we multiplied the AUC0-12 esti-
mated from the twice-daily daptomycin regimen by a fac-
tor of two.
The pharmacokinetic properties of oxacillin [33] and van-
comycin [32] in rat tissue cage fluid were previously
described.
Results and discussion
In vitro studies
The MIC and MBC of daptomycin in CSMHB for MSSA
I20 were 0.5 and 1 mg/L, respectively. The MICs and
MBCs of oxacillin or vancomycin in CAMHB for MSSA
I20 were 0.5 and 1 or 1 and 2 mg/L, respectively.
The MICs of daptomycin for 107 clinical isolates tested
with the same batch of daptomycin as used for the rat tis-
sue cage study were very similar to those reported 10 years
later using more recent daptomycin batches [11,15-18].
Daptomycin MICs were 0.5, 1, and 2 mg/L for 5, 98, and
4 isolates, respectively. These data assessed that the anti-
microbial potency of daptomycin used in the daptomycin
no 1-study was equivalent to that used 10 years later for
the daptomycin no 2-study [37].BMC Infectious Diseases 2006, 6:74 http://www.biomedcentral.com/1471-2334/6/74
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The in vitro elimination rate of exponentially grown
MSSA I20 was more rapid with 8 mg/L of daptomycin
than with equivalent concentrations of oxacillin or vanco-
mycin (Figure 1). The reduction in the viable counts of
strain I20 by daptomycin, oxacillin, and vancomycin
exceeded 3 log10 CFU/mL after 2, 4, and 4 h, respectively.
The more rapid bactericidal activity of daptomycin over
oxacillin and vancomycin was reproduced in three inde-
pendent experiments.
The elimination rate of MSSA I20 by daptomycin was not
significantly affected by supplementation of CSMHB with
50% TCF (data not shown).
Treatment of chronic tissue cage infections
At the onset of therapy, average bacterial counts for 74
cages infected with MSSA I20 were 6.85 ± 0.25 CFU/mL
for controls (n = 19), 6.61 ± 0.19 log10 CFU/mL for ani-
mals receiving daptomycin (n = 18), 6.82 ± 0.20 log10
CFU/mL for animals receiving oxacillin (n = 18), and 6.46
± 0.20 log10 CFU/mL for animals receiving vancomycin (n
= 19). These four sets of bacterial counts did not differ sig-
nificantly from one other.
At the end of the 7-day therapy, average counts in tissue
cages of control, daptomycin-treated, oxacillin-treated,
and vancomycin-treated animals were 7.33 ± 0.14 (n =
19), 3.99 ± 0.34 (n = 18), 5.90 ± 0.25 (n = 18), and 5.49
± 0.21 log10 CFU/mL (n = 19), respectively. Compared to
the control group that showed a slight albeit non-signifi-
cant increase of 0.48 ± 0.24 log10 CFU/mL, all antibiotic
regimens led to significant (P <0.001) reductions in bac-
terial counts in TCF, namely 2.62 ± 0.31 CFU/mL for ani-
mals receiving daptomycin, 0.92 ± 0.21 CFU/ml for
animals receiving oxacillin, and 0.96 ± 0.24 log10 CFU/mL
for animals receiving vancomycin (Figure 2). The mean
reduction in CFU counts in TCF of rats treated with dap-
tomycin was significantly (P < 0.01) higher (>2-fold) than
that of oxacillin- or vancomycin-treated animals.
Pharmacokinetic properties of daptomycin in plasma and 
tissue cage fluid
The pharmacokinetic levels of daptomycin in rat plasma
on day 4 of daptomycin therapy are shown on Figure 3.
On day 4 of administration with twice-daily doses (30
mg/kg) of daptomycin, mean peak and trough plasma lev-
els were 173 and 9.1 mg/L at 1 h and 12 h, respectively.
Similar concentrations of daptomycin were recorded on
day 7 of therapy (data not shown). For comparison, the
peak (141 mg/L) and trough (0 mg/L) plasma levels on
day 4 of administration with once-daily doses (30 mg/kg)
of daptomycin recorded in the daptomycin no 1-study
[37] are represented on Figure 3. The pharmacokinetic
profiles of twice-daily and once-daily regimens of dapto-
mycin are not markedly different besides the much lower
level recorded at 12 h for the once-daily (1 mg/L) com-
pared to twice-daily (9.1 mg/L) dosing. The similar phar-
macokinetic profiles obtained in both independently
conducted studies using two different methods, namely a
microbiological assay and HPLC, provide support to the
reliability of these data and further indicate that the anti-
microbial potency of daptomycin used for the daptomy-
cin no 1-study was equivalent to that used 10 years later
for the daptomycin no 2-study [37]. The plasma AUC0-24h
(1667 mg × h/L) recorded with the twice-daily regimen
was >2-fold higher than the once-daily regimen of 30 mg/
kg daptomycin that yielded a plasma AUC0-24h of 558 mg
× h/L [37].
More striking differences were observed when comparing
pharmacokinetic levels of daptomycin reached in rat TCF
by twice-daily versus once-daily administration of this
antibiotic (Figure 4). Mean peak and trough levels of dap-
tomycin in TCF were 66 and 21 mg/L for rats receiving the
Elimination rates of methicillin-susceptible S. aureus (MSSA)  strain I20 with daptomycin (DAP; 8 mg/L), oxacillin (OXA; 8  mg/L) or vancomycin (VAN; 8 mg/L), assayed in CSMHB  (DAP) or CAMHB (OXA; VAN). These data are from a sin- gle representative experiment and were reproduced three  times Figure 1
Elimination rates of methicillin-susceptible S. aureus (MSSA) 
strain I20 with daptomycin (DAP; 8 mg/L), oxacillin (OXA; 8 
mg/L) or vancomycin (VAN; 8 mg/L), assayed in CSMHB 
(DAP) or CAMHB (OXA; VAN). These data are from a sin-
gle representative experiment and were reproduced three 
times.
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twice-daily daptomycin regimen. In comparison, mean
peak and trough TCF levels of daptomycin were 11.8 and
3.4 mg/L for rats receiving the once-daily daptomycin reg-
imens, with an intermediate value of 10.0 mg/L at 12 h.
The most significant difference in pharmacokinetics was a
ca. 5.5-fold increase in TCF AUC0-24h of rats receiving
twice-daily (1073 mg × h/L) compared to once-daily (196
mg × h/L) regimens of daptomycin.
In rats receiving twice-daily doses of oxacillin (200 mg/
kg) or vancomycin (50 mg/kg), peak and trough TCF lev-
els were 45 and 5.7 or 12 and 2 mg/L, respectively, as
described previously [32,33].
Screening of potential side effects of high-dose 
daptomycin
No exterior sign of toxicity was observed on rats receiving
twice-daily doses of daptomycin. There were no or only
minor changes in activities of marker enzymes of dapto-
mycin-treated (n = 5) vs control (n = 5) animals, namely
216 ± 24 vs 146 ± 36 IU/L for ASAT, 46 ± 9 vs 41 ± 11 IU/
L for ALAT, 53 ± 5 vs 50 ± 5 µM/L for serum creatinine,
and 1393 ± 886 vs 1349 ± 820 IU/L for creatine kinase,
respectively. Thus, only mild liver toxicity was observed in
rats treated with high-dose daptomycin.
General comments
The improved efficacy of the twice-daily 30 mg/kg dapto-
mycin regimen compared to oxacillin (200 mg/kg) or van-
comycin (50 mg/kg) in the rat model of tissue cage
infections by MSSA strain I20 should be discussed in the
light of recent clinical and experimental studies that
explored the safety and efficacy of higher regimens of dap-
tomycin [29,40-42] against serious S. aureus infections
(e.g. bacteremia, endocarditis, osteomyelitis) compared
to the FDA-approved 4 mg/kg daily regimen for CSSSIs.
The in vivo activity of the twice-daily 30 mg/kg daptomy-
cin regimen in MSSA-infected cages was impressive when
compared to the repeatedly low activity of the twice-daily
200 mg/kg regimen of the reference agent oxacillin
recorded in this and a previous study [37]. While promis-
ing results were also recorded in daptomycin-treated rats
infected with the MRSA strain MRGR3, the inadequately
low numbers of control or vancomycin-treated animals
prevented statistical validation of the MRSA arm (data not
shown).
The more rapid in vitro elimination rate of MSSA strain
I20 by daptomycin compared to oxacillin and vancomy-
cin may be one factor potentially explaining its improved
in vivo activity over comparators against tissue cage infec-
tions by MSSA strain I20. An additional contributing fac-
tor seems to be the very high TCF antibiotic levels
resulting from the twice-daily 30 mg/kg daptomycin regi-
men. Nevertheless, a direct comparison between S. aureus
in vivo elimination rates recorded in the daptomycin no
1- and -no 2 studies is not feasible and would require a
correction factor accounting for the 2-fold difference in
daptomycin MICs displayed by the different S. aureus
strains used for those studies.
Despite the fact that current pharmacokinetic models do
not adequately explain the widely different TCF levels
recorded with the twice daily compared to once daily 30
mg/kg daptomycin regimens, we would like to propose
the following interpretation. First, the plasma AUC0-24h of
558 mg × h/L estimated during the daptomycin no 1-
study was considered slightly higher than the average
AUC0-24h of human volunteers receiving a clinical once-
daily dose of 4 mg/kg [37]. Since protein binding of dap-
tomycin is comparable between rodents and humans, it
has been argued that a comparison of total daptomycin
concentrations is appropriate [47]. The plasma levels of
the daptomycin no 1-study were also within the range of
those recorded in a therapeutic rat model of MRSA endo-
carditis, which yielded plasma AUC0-24h of 278 and 605
mg × h/L following daily doses of 25 and 40 mg/kg of
daptomycin, respectively [47]. In particular, the 40 mg/kg
daptomycin daily dose in rats was considered slightly
inferior to the 6 mg/kg daily dose administered to
humans, which was recently shown to be efficient for
therapy of S. aureus bacteremia and endocarditis [40]. Fur-
thermore, another recent study demonstrated the neces-
sity to administer 50 and 60 mg/kg twice-daily
daptomycin regimens for efficient therapy of experimen-
tal osteomyelitis in rabbits [42]. In the same line, the
Decrease in viable counts of methicillin-susceptible S. aureus  (MSSA) in tissue cage fluids of rats treated for 7 days with  twice-daily regimens of either daptomycin (30 mg/kg), oxacil- lin (200 mg/kg), or vancomycin (50 mg/kg). n: number of  cages included in each group Figure 2
Decrease in viable counts of methicillin-susceptible S. aureus 
(MSSA) in tissue cage fluids of rats treated for 7 days with 
twice-daily regimens of either daptomycin (30 mg/kg), oxacil-
lin (200 mg/kg), or vancomycin (50 mg/kg). n: number of 
cages included in each group.
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safety and pharmacokinetics of higher daily regimens of
daptomycin were also explored up to 8 mg/kg [29], and
even more recently up to 12 mg/kg [41] in human volun-
teers.
Nevertheless, it should be stressed that it is not the plasma
but the TCF AUC0-24h of daptomycin which is the true
parameter directly influencing the therapeutic efficacy of
this antibiotic at the local site of S. aureus infection. In the
daptomycin no 1-study, the TCF AUC0-24h of daptomycin
represented only 35% of that recorded in rat plasma,
which indicated an incomplete diffusion of this antibiotic
from the plasma to tissue cage fluid compartment when
administered at the 30 mg/kg daily regimen [37]. In con-
trast, the TCF AUC0-24h of daptomycin administered at the
30 mg/kg twice-daily regimen in the daptomycin no 2-
study was equivalent to 64% of that recorded in rat
plasma. This result might be explained by either improved
diffusion of this antibiotic from the plasma to TCF com-
partment or/and higher accumulation and slower elimi-
nation of this antibiotic in TCF compared to plasma. In
this context, it should be mentioned that daptomycin
pharmacokinetic parameters were shown to become non-
linear at a 8 mg/kg daily regimen including a longer half-
life of elimination in human volunteers [29]. It is there-
fore possible that pharmacokinetic data recorded when
using the twice-daily 30 mg/kg daptomycin regimen in
our rat model also reflected a non-linear pharmacokinetic
response compared to the daptomycin no 1-study, which
was further amplified in TCF compared to plasma com-
partment.
Elaborated pharmacokinetic studies in the immunocom-
promised murine thigh model have defined the AUC/MIC
ratio (range 300-1000) as the pharmacodynamic parame-
ter most predictive of this compound's bactericidal activ-
ity against S. aureus [21-23]. When applied to our rat
model of tissue cage S. aureus infections, the AUC/MIC
ratio of the daptomycin no 1-study would be 98 and that
of the daptomycin no 2-study 1093, which could explain
the improved bacteriological result of the twice-daily over
once-daily 30 mg/kg daptomycin regimens. Nevertheless,
application to the rat model of tissue cage infections of
AUC/MIC ratio breakpoints recorded in neutropenic mice
models is probably not justified because of important dif-
ferences between these animal models. It is noteworthy
that daptomycin therapy is initiated as early as 2 h post S.
aureus infection in neutropenic mice, which may still be in
the range of prophylactic therapies. In contrast, antimicro-
bial therapy in the tissue cage model is not initiated before
2 or 3 weeks of chronic S. aureus infections, which more
closely mimic the clinical situation of foreign body infec-
tions [1]. Finally, the impact of protein binding is less
clearly established in the TCF compared to plasma com-
partment, since we found no significant in vitro reduction
of daptomycin bactericidal activity against MSSA by 50%
TCF in this and the daptomycin no 1-study [37].
Conclusion
In conclusion, our data further emphasise the value of
performing experiments in animals for the primary evalu-
ation of new therapeutic agents. Prediction of the thera-
peutic efficacies of various antibiotics against foreign
body infections may be difficult by relying exclusively on
in vitro pharmacodynamic models derived from pharma-
cokinetic data in the plasma compartment.
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Pharmacokinetic levels of daptomycin in rat plasma on day 4  of therapy with twice-daily (closed symbols) or once-daily  (open symbols) doses of daptomycin (30 mg/kg) Figure 3
Pharmacokinetic levels of daptomycin in rat plasma on day 4 
of therapy with twice-daily (closed symbols) or once-daily 
(open symbols) doses of daptomycin (30 mg/kg). The plasma 
AUC0-24h of rats treated with the twice-daily and once-daily 
regimens were 1667 and 558 mg × h/L, respectively. The val-
ues for each time point are the mean (+ SEM) daptomycin 
plasma levels determined in four different animals.
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